Hedvig Nordeng is a professor and head of the Pharmacoepidemiology and Drug Safety Research Group at the Faculty of Mathematics and Natural Sciences at the University of Oslo, Norway.
Her research interests and expertise are in perinatal pharmacoepidemiology and pharmacotherapy during pregnancy and breast feeding.
Professor Nordeng is the holder of ERC STG Grant “DrugInPregnancy”. Dr. Nordeng is also head of the PharmaTox Strategic Research Initiative at the Faculty of Mathematics and Natural Sciences, University of Oslo, Norway uniting 50 researchers within Life Sciences at the MN Faculty, and the head of the National Research School in Pharmacy, uniting more than 100 PhD students in pharmaceutical sciences in Norway. She has hosted guest scientists from USA, Austria, Sweden, The Netherlands and UK and supervised student exchanges through the Erasmus program.
She is currently the chair of the Medications in Pregnancy and Breast feeding (MiPaL) Special interest group (SIG) at ISPE (2018-2020).
As of 2018 she is an independent scientific expert in the Pharmacovigilance Risk Assessment Committee (PRAC) which is the European Medicines Agency's (EMA) committee responsible for assessing and monitoring the safety of human medicines.
She has a PhD in perinatal pharmacoepidemiology and pharmacotherapy, Faculty of Medicine, University of Oslo in 2005. MSc Pharm in 1997. Dr. Nordeng became a full professor at the Faculty of Mathematics and Natural Sciences, University of Oslo, Norway in 2011.
Dr. Nordeng has authored over 150 scientific articles, book chapters and national guidelines on drug use in pregnancy and lactation.